MXPA96005327A - Use of certain derivatives of acidometanisphisphonic to prevent the loosening of protesis and the emigration of proteins - Google Patents
Use of certain derivatives of acidometanisphisphonic to prevent the loosening of protesis and the emigration of proteinsInfo
- Publication number
- MXPA96005327A MXPA96005327A MXPA/A/1996/005327A MX9605327A MXPA96005327A MX PA96005327 A MXPA96005327 A MX PA96005327A MX 9605327 A MX9605327 A MX 9605327A MX PA96005327 A MXPA96005327 A MX PA96005327A
- Authority
- MX
- Mexico
- Prior art keywords
- acid
- diphosphonic acid
- diphosphonic
- hydroxy
- hydroxypropan
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 239000002253 acid Substances 0.000 claims abstract description 79
- -1 1- (4-chlorothiophenyl) methan-1,1-diphosphonic acid Chemical compound 0.000 claims abstract description 42
- 239000011780 sodium chloride Substances 0.000 claims abstract description 33
- 150000003839 salts Chemical class 0.000 claims abstract description 31
- WRUUGTRCQOWXEG-UHFFFAOYSA-N Pamidronic acid Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 claims abstract description 16
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 claims abstract description 12
- PQBAWAQIRZIWIV-UHFFFAOYSA-N Methylpyridinium Chemical class C[N+]1=CC=CC=C1 PQBAWAQIRZIWIV-UHFFFAOYSA-N 0.000 claims abstract description 11
- PUUSSSIBPPTKTP-UHFFFAOYSA-N Neridronic acid Chemical compound NCCCCCC(O)(P(O)(O)=O)P(O)(O)=O PUUSSSIBPPTKTP-UHFFFAOYSA-N 0.000 claims abstract description 7
- PRDQWHLWOXBNMT-UHFFFAOYSA-N [2-(dimethylamino)-1-hydroxy-1-phosphonopropyl]phosphonic acid Chemical compound CN(C)C(C)C(O)(P(O)(O)=O)P(O)(O)=O PRDQWHLWOXBNMT-UHFFFAOYSA-N 0.000 claims abstract description 7
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 claims abstract description 6
- RDFHOSXBGDLRQF-UHFFFAOYSA-N (2-anilino-1-phosphono-2-sulfanylideneethyl)phosphonic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)C(=S)NC1=CC=CC=C1 RDFHOSXBGDLRQF-UHFFFAOYSA-N 0.000 claims abstract 4
- RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 241000124008 Mammalia Species 0.000 claims description 10
- XQRLCLUYWUNEEH-UHFFFAOYSA-N diphosphonic acid Chemical compound OP(=O)OP(O)=O XQRLCLUYWUNEEH-UHFFFAOYSA-N 0.000 claims description 10
- 210000001624 Hip Anatomy 0.000 claims description 9
- 230000005012 migration Effects 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 9
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 8
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 claims description 7
- 238000001990 intravenous administration Methods 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 5
- ACSIXWWBWUQEHA-UHFFFAOYSA-N Clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 claims description 5
- DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 claims description 4
- XRASPMIURGNCCH-UHFFFAOYSA-N Zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims description 4
- QWCNOXMFNSYEKF-UHFFFAOYSA-N [1-hydroxy-3-[methyl(2-phenylsulfanylethyl)amino]-1-phosphonopropyl]phosphonic acid Chemical compound OP(=O)(O)C(O)(P(O)(O)=O)CCN(C)CCSC1=CC=CC=C1 QWCNOXMFNSYEKF-UHFFFAOYSA-N 0.000 claims description 4
- 229960005324 tiludronic acid Drugs 0.000 claims description 4
- 229960004343 Alendronic acid Drugs 0.000 claims description 3
- MPBVHIBUJCELCL-UHFFFAOYSA-N bondronat Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000003981 vehicle Substances 0.000 claims description 3
- UGEPSJNLORCRBO-UHFFFAOYSA-N [3-(dimethylamino)-1-hydroxy-1-phosphonopropyl]phosphonic acid Chemical compound CN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O UGEPSJNLORCRBO-UHFFFAOYSA-N 0.000 claims description 2
- BOTDANWDWHJENH-UHFFFAOYSA-N Tetraethyl orthosilicate Chemical compound CCO[Si](OCC)(OCC)OCC BOTDANWDWHJENH-UHFFFAOYSA-N 0.000 claims 6
- CPDHVIDLBUSJJG-UHFFFAOYSA-N (3-benzoyl-5-phosphono-1,4-dihydropyrazol-5-yl)phosphonic acid Chemical compound N1C(P(O)(=O)O)(P(O)(O)=O)CC(C(=O)C=2C=CC=CC=2)=N1 CPDHVIDLBUSJJG-UHFFFAOYSA-N 0.000 claims 2
- GSRGEFWQJOOSBC-UHFFFAOYSA-N C(C1=CC=CC=C1)(=O)C1=NNCC1 Chemical compound C(C1=CC=CC=C1)(=O)C1=NNCC1 GSRGEFWQJOOSBC-UHFFFAOYSA-N 0.000 claims 1
- 229940088130 Pamidronate Disodium Drugs 0.000 claims 1
- 230000002378 acidificating Effects 0.000 claims 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 1
- 229960003978 pamidronic acid Drugs 0.000 claims 1
- KAESVJOAVNADME-UHFFFAOYSA-N pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 abstract description 2
- PMXAPNNYCFBALB-UHFFFAOYSA-N (1-hydroxy-1-phosphono-3-pyrrolidin-1-ylpropyl)phosphonic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CCN1CCCC1 PMXAPNNYCFBALB-UHFFFAOYSA-N 0.000 abstract 1
- MXYOPVWZZKEAGX-UHFFFAOYSA-N 1-phosphonoethylphosphonic acid Chemical compound OP(=O)(O)C(C)P(O)(O)=O MXYOPVWZZKEAGX-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 description 24
- 239000000203 mixture Substances 0.000 description 19
- 229940112871 Bisphosphonate drugs affecting bone structure and mineralization Drugs 0.000 description 14
- 150000004663 bisphosphonates Chemical class 0.000 description 12
- 210000000988 Bone and Bones Anatomy 0.000 description 11
- 239000000243 solution Substances 0.000 description 9
- 239000002775 capsule Substances 0.000 description 8
- 239000011248 coating agent Substances 0.000 description 8
- 238000000576 coating method Methods 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 239000008187 granular material Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 239000000454 talc Substances 0.000 description 6
- 235000012222 talc Nutrition 0.000 description 6
- 229910052623 talc Inorganic materials 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241000906034 Orthops Species 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 239000008298 dragée Substances 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 239000007943 implant Substances 0.000 description 5
- 239000000825 pharmaceutical preparation Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 5
- 208000006386 Bone Resorption Diseases 0.000 description 4
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 4
- 210000004051 Gastric Juice Anatomy 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 229920002367 Polyisobutene Polymers 0.000 description 4
- 230000024279 bone resorption Effects 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 230000011164 ossification Effects 0.000 description 4
- 230000036961 partial Effects 0.000 description 4
- 229920001592 potato starch Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 3
- 208000001132 Osteoporosis Diseases 0.000 description 3
- 210000003491 Skin Anatomy 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229940046231 pamidronate Drugs 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 229960000759 risedronic acid Drugs 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- YJISHJVIRFPGGN-UHFFFAOYSA-N 5-[5-[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxy-6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical compound O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)O)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 YJISHJVIRFPGGN-UHFFFAOYSA-N 0.000 description 2
- 229960002286 Clodronic Acid Drugs 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 210000003414 Extremities Anatomy 0.000 description 2
- 206010020583 Hypercalcaemia Diseases 0.000 description 2
- 208000003393 Mammary Paget's Disease Diseases 0.000 description 2
- 208000010191 Osteitis Deformans Diseases 0.000 description 2
- 241000283898 Ovis Species 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000018678 bone mineralization Effects 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- CZYWHNTUXNGDGR-UHFFFAOYSA-L disodium;(3-amino-1-hydroxy-1-phosphonatopropyl)phosphonic acid;pentahydrate Chemical compound O.O.O.O.O.[Na+].[Na+].NCCC(O)(P(O)([O-])=O)P(O)([O-])=O CZYWHNTUXNGDGR-UHFFFAOYSA-L 0.000 description 2
- 229940079593 drugs Drugs 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000000148 hypercalcaemia Effects 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000003287 optical Effects 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical class [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000001069 triethyl citrate Substances 0.000 description 2
- 235000013769 triethyl citrate Nutrition 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- HLNJFEXZDGURGZ-UHFFFAOYSA-M 1-methylpyridin-1-ium;iodide Chemical class [I-].C[N+]1=CC=CC=C1 HLNJFEXZDGURGZ-UHFFFAOYSA-M 0.000 description 1
- IVFGIXMLURJXBZ-UHFFFAOYSA-N 1-phosphonopropylphosphonic acid Chemical compound CCC(P(O)(O)=O)P(O)(O)=O IVFGIXMLURJXBZ-UHFFFAOYSA-N 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N 2-Pyrrolidone Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N 2-methyl-2-propenoic acid methyl ester Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- XJKJWTWGDGIQRH-BFIDDRIFSA-N Alginic acid Chemical compound O1[C@@H](C(O)=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](C)[C@@H](O)[C@H]1O XJKJWTWGDGIQRH-BFIDDRIFSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 210000004369 Blood Anatomy 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L Calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229940009626 Etidronate Drugs 0.000 description 1
- 229920003136 Eudragit® L polymer Polymers 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 229940014259 Gelatin Drugs 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 210000003127 Knee Anatomy 0.000 description 1
- 229960002900 Methylcellulose Drugs 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920005987 OPPANOL® Polymers 0.000 description 1
- 229920002402 Oppanol® B 100 Polymers 0.000 description 1
- 208000003076 Osteolysis Diseases 0.000 description 1
- 208000001164 Osteoporotic Fracture Diseases 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N Oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 229960000625 Oxytetracycline Drugs 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- 241000282322 Panthera Species 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 229940100486 RICE STARCH Drugs 0.000 description 1
- 206010038001 Rebound effect Diseases 0.000 description 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 1
- 229940089617 Risedronate Drugs 0.000 description 1
- 210000002966 Serum Anatomy 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N Silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- 229940019375 Tiludronate Drugs 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 229940116362 Tragacanth Drugs 0.000 description 1
- 229940100640 Transdermal System Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940100445 WHEAT STARCH Drugs 0.000 description 1
- NPLHDPAQRZJWHX-UHFFFAOYSA-N [5,5-bis(diethoxyphosphoryl)-1,4-dihydropyrazol-3-yl]-phenylmethanone Chemical compound N1C(P(=O)(OCC)OCC)(P(=O)(OCC)OCC)CC(C(=O)C=2C=CC=CC=2)=N1 NPLHDPAQRZJWHX-UHFFFAOYSA-N 0.000 description 1
- KVUUQMDVROTSNI-UHFFFAOYSA-N [morpholin-4-yl(phosphono)methyl]phosphonic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)N1CCOCC1 KVUUQMDVROTSNI-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000240 adjuvant Effects 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940040563 agaric acid Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229910000394 calcium triphosphate Inorganic materials 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007931 coated granule Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000005712 crystallization Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000005553 drilling Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- 230000003054 hormonal Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000019691 monocalcium phosphate Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 230000000399 orthopedic Effects 0.000 description 1
- 230000003204 osmotic Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- RFWLACFDYFIVMC-UHFFFAOYSA-D pentacalcium;[oxido(phosphonatooxy)phosphoryl] phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O RFWLACFDYFIVMC-UHFFFAOYSA-D 0.000 description 1
- 230000000737 periodic Effects 0.000 description 1
- 229940021222 peritoneal dialysis Isotonic solutions Drugs 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 230000001739 rebound effect Effects 0.000 description 1
- 230000002829 reduced Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000630 rising Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 239000011778 trisodium citrate Substances 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Abstract
The present invention relates to the use of a methanobisphosphonic acid derivative selected from: 3-amino-1-hydroxypropan-1,1-diphosphonic acid, 3- (N, N-dimethylamino-1-hydroxypropan-1,1- Diphosphonic acid, 4-amino-1-hydroxybutan-1,1-diphosphonic acid, 6-amino-1-hydroxyhexan-1,1-diphosphonic acid, 3- (N-methyl-Nn-pentylamino) -1-hydroxypropane 1,1-di phosphonic acid, 1-hydroxy-2- (imidazol) -1-yl) ethane-1,1-diphosphonic acid, 1-hydroxy-2- (3-pyridyl) ethane-1,1-diphosphonic acid, and N-methyl pyridinium salts thereof: 1- (4-chlorothiophenyl) methan-1,1-diphosphonic acid, 3- [N- (2-phenylthioethyl) -N-methylamino-1-hydroxypropane-1, 1 -diphosphonic acid, 1-hydroxy-3- (pyrrolidin-1-yl) propan-1,1-diphosphonic acid, 1- (N-phenylaminothiocarbonyl) methan-1,1-diphosphonic acid, 5-benzoyl-3-tetraethyl ester , 4-dihydro-2H-pyrazole-3,3-diphosphonic acid, 1-hydroxy-2- (imidazo [1,2-a] pyridin-3-yl) ethan-1,1-d ifosphonic acid, and acid 1.1 -dichloromethane-1,1-diphosphonic acid, or a pharmaceutical salt you acceptable of them, or any hydrate of the same
Description
USE OF CERTAIN METABANPHISPHONIC ACID DERIVATIVES TO PREVENT LOOSENING OF THE PROSTHESIS AND EMIGRATION
OF THE PROSTHESIS
Arthroplasty, especially of the hip joint, is now a common procedure for the treatment of patients with osteoarthritis, rheumatoid arthritis, and osteoporotic fracture. Approximately 800,000 hip replacements are performed globally each year. This number is rising steadily, and younger patients are being treated, and patients are living much longer and everyone hopes to lead an independent and mobile life. Despite the indisputable success of this technique, complications frequently occur, and occasionally they may require expensive surgical revision.
(not being rare three or four revisions for a single patient). The most common complications are loosening of the aseptic prosthesis [see, for example, H. Marchau et al.,
Acta Orthop. Scand. 64 (1993) 497-506; R.D. Mulroy Jr, and W.H. Harris, J. Bone Joipt Surg. (Br) 72-B (1990) 757-760; M. Winter et al., Clin. Orthop. I laughed Research 282 (1992) 73-80], and the migration of the prosthesis through the bone without obvious loosening [see, for example, B.B. Wroblewski and P.D. Siney, Clin. Orthop. I laughed Research 285 (1992) 45-47; M. Winter et al., Loe. cit.]. These complications result in considerable morbidity, such as pain and mobility
reduced. They occur with both cemented and uncemented prostheses, regardless of design, material, or coating. Different approaches to prevent these complications have focused on the alterations to the design of the prosthesis and the selection of different materials for its construction [see, for example, H. Marchau et al., Loe. cit .; R.D. Mulroy Jr. and W. H. Harris, loe. cit .; M. Winter et al., Loe. cit .; B.B. Wroblewski and P.D. Siney, loe. cit .; J. Wilson-MacDonald et al., J. Bone Joint Surg. (Br) 72-B (1990) 423-430]. Apart from some preliminary research with nonsteroidal apti-inflammatory drugs [A. Ohlin and U.H. Lerner, Bone and Mineral 20 (1993) 67-78; J.H. Herman et al., J. Rheumatol. 21 (1994) 338-343], a pharmacological approach to prevent or treat complications of arthroplasty, especially hip arthroplasty, has not been successful. Metanbisphosphonic acid derivatives, in particular bisphosphonate compounds (= bisphosphopates), are used clinically to inhibit excessive bone resorption in a variety of diseases, such as tumor-induced osteolysis, Paget's disease, and osteoporosis [H. Fleisch, Handbook of Expl. Pharmacol. 83 (1988) 441-465]. Radiolabelled bisphosphonates are also used in diagnosis to identify sites of high bone turnover [B.D. Collier et al., J. Nucí. Med. 34 (1993) 2241-2246; I. Fogelman and
collaborators, J. Nucí. Med. 34 (1993) 2247-2252]. In the orthopedic field in general, there is a strong prejudice against the use of bisphosphonates. First, attempts to use commercially available bisphosphonate etidronate in the prevention of heterotopic ossification - which is another complication after arthroplasty, but very different from loosening of the prosthesis and migration of the prosthesis - were ineffective, or even harmful, due to a rebound effect [see, for example, DE Garland, Clin. Orthop. I laughed Research 263 (1991) 13-29; B.J. Thomas and H.C. Amstutz, The Hip 1987, 59-69; B.J. Thomas, Orthop. Clin. North America 23 (1992) 347-358]. In addition, there is growing evidence that some bisphosphonates can inhibit bone formation and mineralization. Kanis, for example, describes in Lancet 1984, 27-33, that bisphosphonates, as inhibitors of bone resorption, can delay the repair of icro fractures, reducing the speed of remodeling. As another example, Reid et al., In Lancet 1988, 143-146, discovered that the bisphosphonate treatment, in this particular case, made with disodic pamidronate, caused a reduction in bone formation, and a very low rate of bone turnover. raised the possibility of damaging microfracture repair. Ada and collaborators [Lancet 342 (1993) 1459-1460] report that pamidronate can inhibit bone mineralization in the disease
of Paget. Surprisingly, it has now been discovered that certain metapbisphosphonic acid derivatives are useful for the prevention or treatment of these replacement complications
of the joint, at an effective cost, especially hip replacement, in mammals, including man. This can be demonstrated by appropriate tests in vitro and in vivo. In particular, the experiments in vivo show that the bisphosphonates according to the invention are effective
to prevent loosening of prosthesis in treated animals, for example, sheep. This is demonstrated, for example, by the following test methods: 12 adult female sheep, approximately 50 kilograms of body weight, are randomly divided into two groups of 6 animals, and all
suffer a total unilateral hip replacement operation with implantation of a titanium prosthesis. Immediately after surgery, one group of animals receives an intravenous infusion of bisphosphonate, and the other group receives serum. This treatment can be repeated subsequently, for example, at
4 and at 8 weeks. At regular monthly intervals, the hip and femoral region of each animal is subjected to digital radiography, both standard and quantitative, to assess changes in bone density around the prosthesis, as an early indicator of loosening of the prosthesis. In addition,
the animals are made to walk on a force plate of
"Kistler" to measure the strength of reaction to the vertical floor of both limbs prevented, to determine the functionality of the limb, and indirectly, the pain. At 12 months after the operation, and 2 weeks before slaughter, the animals receive a double injection, 10 days apart, of the osseous fluorescent label oxytetracycline, to facilitate the histomorphometric analysis. At the end of the labeling period, the
"** 'animals are sacrificed and the femurs are removed with the implants for post-mortem analysis.
accurately polished the femurs, undergo icrorradiography to determine bone loss around the implant. Similar sections are also analyzed by histomorphometry to evaluate bone resorption and formation at the tissue level. Finally, sections of the bone that the implant contains
undergo a mechanical "push out" mechanical test on a material testing machine to measure the strength of the bond between the metal implant and the surrounding bone. A comparison of test animals treated with
A bisphosphonate according to the invention, with the controls, clearly shows that the bisphosphonate treatment is beneficial to prevent and treat the loosening of the prosthesis. Accordingly, the invention relates to the use of a methanobisphosphonic acid derivative selected from:
3-amino-l-hydroxypropan-1, 1-diphosphonic acid (acid
pamidronic), for example, pamidronate; 3- (N, N-dimethylamino) 1-hydroxypropan-1, 1-diphosphonic acid, for example, di-ethyl-APD; 4-amino-l-hydroxybutap-1, 1-diphosphonic acid (alendronic acid), for example, alepdronate; 6-amino-l-hydroxyhexan-1,1-diphosphonic acid, for example, to ino-hexyl-BP; acid
3- (N-methyl-N-n-pentylamino) -l-hydroxypropan-1, 1-diphosphonic, for example, ethyl-pentyl-APD (= BM 21.0955); l-hydroxy-2- (i idazol-1-yl) ethan-1, 1-diphosphonic acid; l-hydroxy-2- (3-pyridyl) ethan-1, 1-diphosphonic acid (risedronic acid), for example, risedronate, including N-methyl pyridinium salts thereof, for example, N-methyl pyridinium iodides such as NE-10244 or NE-10446; l- (4-chlorothiophenyl) methan-1, 1-diphosphonic acid (tiludronic acid), for example, tiludronate; 3- [N- (2-phenylthioethyl) -N-methyl amino] -1-hydroxy ipropan-1, 1-diphosphonic acid; l-hydroxy-3- (pyrrolidip-l-yl) propan-l, 1-diphosphonic acid, for example, EB 1053 (Leo); 1- (N-phenylamothiocarbonyl) methan-1,1-diphosphonic acid, for example, FR 78844 (Fujisawa); 5-benzoyl-3,4-dihydro-2H-pyrazole-3,3-diphosphonic acid tetraethyl ester, for example, U-81581 (Upjohn); l-hydroxy-2- (imidazofl, 2-a] pyridin-3-yl) ethan-1, 1-diphosphonic acid, for example, YM 529; 1, 1-dichloromethane-1, 1-diphosphonic acid (clodronic acid), for example, clodronate; or a pharmaceutically acceptable salt thereof, or any hydrate thereof, (for the manufacture of a pharmaceutical composition) for the prevention and treatment of prosthetic loosening and
emigration of prostheses in mammals, including man. As previously mentioned, prosthetic loosening and prosthesis migration frequently appears as a complication after arthroplasty. The arthroplasty 5 means a partial, for example, partial or total arthroplasty of any joint, especially of the hip and knee, and in particular of the hip. , * "The pharmaceutically acceptable salts are preferably salts with bases, conveniently metal salts derived from the groups Ia, Ib, Ha, and Ib from the Periodic Table of the Elements, including alkali metal salts, for example. salts of potassium and especially of sodium, or alkaline earth metal salts, preferably calcium or magnesium salts, and also ammonium salts with ammonia or organic amines r The pharmaceutically acceptable salts are especially preferred where one, two , three, or four, in particular one or two of the acid hydrogens of bisphosphonic acid, are replaced by a pharmaceutically cation
acceptable, in particular sodium, potassium, or ammonium, in the first instance sodium. A most preferred group of pharmaceutically acceptable salts is characterized by having an acid hydrogen and a pharmaceutically acceptable cation, especially sodium, in each
one of the phosphonic acid groups.
All the metapbisphosphonic acid derivatives mentioned above are well known from the literature. This includes its manufacture (see, for example, U.S. Patent Number EP-A-513,760, pages 13-48). For example, 3-amylo-l-hydroxypropan-1, 1-diphosphoic acid is prepared as described, for example, in U.S. Patent No. 3,962,432, as well as in U.S. Pat. Numbers 4,639,338 and 4,711,880, and l-hydroxy-2- (imidazol-1-yl) ethan-1, 1-diphosphonic acid is prepared as described, for example, in U.S. Patent No. 4,939,130. A particular embodiment of the invention is represented by the use of an ethanobisphosphonic acid derivative, which is selected from 3-amino-l-hydroxypropan-1,1-diphosphonic acid, 3- (N, N-dimethylamino- 1-hydroxypropan-1, 1-diphosphonic acid, 4-amino-1-hydroxybutan-1, 1-diphosphonic acid, 6-amino-1-hydroxyhexan-1, 1-diphosphonic acid, 3- (N-methyl 1-Nn) acid -pentylamino) -1-hydroxy-propan-1,1-diphosphonic acid, l-hydroxy-2- (imidazol-1-yl) ethane-1,1-diphosphonic acid, l-hydroxy-2- (3-pyridyl) ethan-1, 1-diphosphonic, and N-methyl pyridinium salts thereof; l- (4-chlorothiophenyl) methan-1, 1-diphosphonic acid, 3- [N- (2-phenylthioethyl) -N-methylamino] ] -l-hydroxypropan-1, 1-diphosphonic acid, l-hydroxy-3-
pyrrolidin-1-yl) propan-1,1-diphosphonic acid, 1- (N-phenylaminothiocarbonyl) ethane-1,1-diphosphonic acid, 5-benzoyl-3,4-dihydro-2H-pyrazole-3-tetraethyl ester, 3-diphosphonic acid, l-hydroxy-2- (imidazo [1,2- a] pyridin-3-yl) ethane-1,1-diphosphonic acid, a pharmaceutically acceptable salt thereof, and any hydrate thereof. A preferred embodiment of the invention is represented by the use of an acid derivative
- methanbisphosphonic acid, which is selected from 3-amino-1-hydroxypropan-1, 1-diphosphonic acid, 3- (N, N-dimethylamino-1-hydroxypropan-1, 1-diphosphonic acid, 4-amino acid) l-hydroxybutan-1,1-diphosphonic acid, 6-amino-l-hydroxyhexan-1, 1-diphosphnanoic acid, 3- (N-methyl-Nn-pentylamino) -1-hydroxypropan-1, 1- diphosphonic acid, -hydroxy-2- (imidazol-1-yl) ethan-1, 1- diphosphonic acid l-hydroxy-2- (3-pyridyl) ethane-1,1-diphosphonic acid, 3- [N- (2-phenylthioethyl) ) -N-methylamino] -1-hydroxypropan-1, 1-r-diphosphonic acid l-hydroxy-3- (pyrrolidin-1-yl) propan-l, 1- diphosphonic acid, l-hydroxy-2- ( imidazo [1,2- a] pyridin-3-yl) ethan-1,1-diphosphonic acid, a pharmaceutically acceptable salt thereof, and any hydrate thereof.
A most preferred embodiment of the invention is represented by the use of a methanobisphosphonic acid derivative, which is selected from pamidridnic acid, alendronic acid, 3- (N-methyl-N-n-
pentylamino) -l-hydroxypropan-1, 1-diphosphonic acid, l-hydroxy-2- (imidazol-1-yl) ethan-1, diphosphonic acid, risedronic acid, and tiludronic acid, a pharmaceutically acceptable salt thereof, and any hydrate thereof. An especially preferred embodiment of the invention is represented by the use of a metapbisphosphonic acid derivative, which is selected from 1-hydroxy-2- (imidazol-1-yl) ethan-1, 1-diphosphonic acid, and acid 3-amino-1-hydroxypropan-1, 1-diphosphonic acid, a pharmaceutically acceptable salt thereof, and any hydrate thereof. In addition, the invention relates to the use of 1-hydroxy-2- (imidazol-1-yl) ethan-1, 1-diphosphonic acid or a pharmaceutically salt thereof or any hydrate thereof. In addition, the invention relates to the use of 3-amino-1-hydroxypropan-1,1-diphosphoic acid or a pharmaceutically acceptable salt thereof or any hydrate thereof. The pharmaceutically useful methanobisphosphonic acid derivatives can be used in the form of a possible isomer or a mixture of isomers, typically as optical isomers, such as enantiomers or diastereoisomers or geometric isomers, typically cis-trans isomers. The optical isomers are obtained in the form of pure antipodes and / or as racemates. The pharmaceutically useful methansulfonic acid derivatives can also be used in the form
and &e its hydrates, or may include other solvents used for its crystallization. The methanobisphosphonic acid derivative is preferably used in the form of a pharmaceutical preparation containing a therapeutically effective amount of the active ingredient, optionally together with, or in admixture with, inorganic or organic, solid or liquid, pharmaceutically acceptable carriers, which are suitable for the administration. The pharmaceutical compositions can be, for example, compositions for enteral administration, such as oral, rectal, aerosol inhalation, or nasal, compositions for parenteral administration, such as intravenous or subcutaneous administration, or compositions for transdermal administration (e.g., passive or iontophoretic). In addition, direct local administration is considered at the time of the operation. What the last type of administration means is the coating of the exposed bone surface to which the implant is attached, with a bisphosphonate according to the invention, for example, by washing the surface of the bone with a bisphosphonate solution. What does not mean this type of administration, is the coating of the prosthesis with bisphosphonates. Preferably, the pharmaceutical compositions are adapted for oral or parenteral administration (especially intravenous or transdermal) before, during or after implanting the prosthesis, or for local administration during implantation
of the prosthesis. Intravenous and oral administration, first of all intravenously, is considered of particular importance. The particular mode of administration and administration will be selected by the attending physician, taking into account the particulars of the patient, especially age, weight, lifestyle, level of activity, hormonal status (for example, after the menopause), bone mineral density, and the type of prosthesis that will be implanted. The dosage of the active ingredient may depend on different factors, such as the effectiveness and duration of action of the active ingredient, the mode of administration, the warm blood species, and / or sex, age, weight, and condition. individual of the warm-blooded animal. Typically, the dosage is such that a single dose of 0.002 to 3.40 milligrams / kilogram, especially 0.01 to 2.40 milligrams / kilogram, is administered to a warm-blooded animal weighing approximately 75 kilograms. If desired, this dose can also be taken in several partial, optionally equal doses. "milligrams / kilogram" means milligrams of the drug per kilogram of body weight of the mammal - including the man - to be treated. The dose mentioned above - either administered as a single dose (which is preferred) or in several doses
partial - can be repeated, for example, once a day, once a week, once a month, once every three months, once every six months, or once a year. In other words, the pharmaceutical compositions can be administered in regimens from a continuous daily therapy, to an intermittent cyclic therapy. Preferably, methanobisphosphonic acid derivatives are administered in doses of the same order of magnitude as those used in the treatment of diseases conventionally treated with methanobisphosphonic acid derivatives, such as Paget's disease, tumor-induced hypercalcemia, or osteoporosis. . In other words, preferably the methanobisphosphonic acid derivatives are administered in doses that would be therapeutically effective in the treatment of diseases of
Paget, tumor-induced hypercalcemia, or osteoporosis, that is, they are preferably administered in doses that would effectively inhibit bone resorption. Formulations in a single unit dosage form preferably contain from about 1 percent to about 90 percent, and formulations that are not in a unit dosage form contain about 0.1 percent a approximately 20 percent of the active ingredient. Unitary forms of a single dose, such as capsules,
Tablets, or dragees, contain, for example, from about 1 milligram to about 500 milligrams of the active ingredient. The invention further relates to the use of a composition for the manufacture of a medicament, for example, in a unitary single-dose form, for the prevention and treatment of prosthetic loosening and migration of prostheses in mammals, including man, in wherein the composition contains from 0.002 to 3.40 milligrams / kilogram, especially from 0.01 to 2.40 milligrams / kilogram, of a methanbisphosphonic acid derivative as defined above, by dosage form. Moreover, the invention relates to the use of a methanobisphosphonic acid derivative as defined above, in a dose of 0.002 to 3.40 milligrams / kilogram, especially 0.01 to 2.40 milligrams / kilogram, per dosage form, for the manufacture of a medicine for the prevention and treatment of prosthesis loosening and emigration of prostheses in mammals, including man. Pharmaceutical preparations for enteral and parenteral administration are, for example, those which are in unit dosage forms, such as dragees, tablets, or capsules, and also ampoules. They are prepared in a manner known per se, for example, by means of conventional mixing, granulating, confectioning, dissolving, or
lyophilization. For example, pharmaceutical preparations for oral administration can be obtained by combining the active ingredient with solid carriers, where it is appropriate to granulate a resulting mixture, and process the mixture or granulate, if desired or necessary, after the addition. of the appropriate auxiliaries, in tablets or dragee cores. Suitable carriers are especially fillers, such as sugars, for example, lactose, sucrose, mannitol, or sorbitol, cellulose preparations and / or calcium phosphates, for example, calcium triphosphate or calcium acid phosphate, and also binders, such as as starch pastes, using, for example, corn starch, wheat starch, rice starch, or potato starch, gelatin, tragacanth, methyl cellulose, and / or polyvinyl pyrrolidone, and if desired, disintegrators, such as the aforementioned starches , and also carboxymethyl starch, cross-linked polyvinyl pyrrolidone, agar or alginic acid or a salt thereof, such as sodium algipate. Auxiliaries are especially flow regulators and lubricants, for example, silicic acid, talc, stearic acid, or salts thereof, such as magnesium or calcium stearate, and / or polyethylene glycol. Dragee cores are provided with suitable coatings that can be resistant to gastric juices, using, among others, concentrated sugar solutions that optionally contain gum arabic, talc, polyvinyl polyglycol pyrrolidone, and / or
titanium dioxide, or lacquer solutions in suitable organic solvents or solvent mixtures, or, to produce coatings that are resistant to gastric juices, solutions of suitable cellulose preparations, such as acetyl cellulose phthalate, or hydroxypropylmethyl cellulose phthalate . Colorants or pigments can be added to tablets or dragee coatings, for example, for identification purposes, or to indicate different doses of the active ingredient. Other pharmaceutical preparations that can be administered orally are dry-filled capsules made of gelatin, and also sealed soft capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The dry-filled capsules can contain the active ingredient in the form of a granulate, for example, mixed with fillers, such as lactose, binders, such as starches, and / or brighteners, such as talc or magnesium stearate, and wherein be appropriate, stabilizers. In soft capsules, the active ingredient is preferably dissolved or suspended in suitable liquids, such as fatty oils, paraffin oil, or liquid polyethylene glycols, it also being possible for stabilizers to be added. Parenteral formulations are especially injectable fluids that are effective in different ways, such as intravenously, intramuscular ep,
intraperitopeally, intranasally, ipradermally, or subcutaneously. These fluids are preferably aqueous, isotonic solutions or suspensions, which can be prepared before use, for example, from freeze-dried preparations containing the active ingredient alone or together with a pharmaceutically acceptable carrier. The pharmaceutical preparations can be sterilized and / or can contain and adjuvants, for example, preservatives, stabilizers, wetting agents, and / or emulsifiers, solubilizers, salts for
regulate the osmotic pressure, and / or pH regulators. Formulations suitable for transdermal application include an effective amount of the active ingredient with a carrier. Convenient vehicles include pharmacologically acceptable solvents that can be absorbed,
to assist in passing through the skin of the host. In a characteristic manner, the transdermal devices are in the form of a bandage comprising a backing member, a reservoir containing the compound optionally with vehicles, optionally a speed control barrier for applying the
Active ingredient to the skin of the host at a controlled rate and previously determined for a prolonged period of time, and elements to secure the device to the skin. The following examples illustrate the invention described hereinabove. The term "active ingredient"
should be understood as any of the acid derivatives
methanobisphosphonic substances mentioned above as useful according to the present invention.
Example 1: Capsules containing granules coated with, for example, disodium pamidronate pentahydrate, as the active ingredient: Core granule: active ingredient (ground) 197.3 milligrams microcrystalline cellulose (Avicel PH 105) 52.7 milligrams
250. 0 milligrams
+ Internal coating: HP-M 603 cellulose 10.0 milligrams
Polyethylene glycol 2.0 milligrams Talco 8.0 milligrams
270. 0 milligrams
+ External coating resistant to gastric juice: Eudragit »L30 D (solid) 90.0 milligrams Triethyl citrate 21.0 milligrams
Antiespumapte AF 2.0 milligrams Water Talca 7.0 milligrams
390. 0 milligrams
A mixture of disodium pamidronate with Avicel PH 105, moistened with water and kneaded, extruded, and formed into spheres. The dried granules are then successively coated in the fluidized bed with an internal coating, consisting of cellulose HP-M 603, polyethylene glycol (PEG) 8000, and talc, and the coating resistant to aqueous gastric juice, consisting of Eudragit L 30 D, triethyl citrate, and Aptiespumante AF. The coated granules are pulverized with talc and filled into capsules (capsule size 0) by means of a commercial capsule or filling machine, for example, "Hofliger and Karg".
Element 2: Monolithic adhesive transdermal system containing, as an active ingredient, for example, 1-hydroxy-2- (imidazol-1-yl) -ethan-1, 1-diphosphonic acid: 5 Composition:
Polyisobutylene (PIB) 300 5.0 grams (Oppanol Bl, BASF) 0 PIB 35000 3.0 grams (Oppapol B10, BASF) PIB 1200000 9.0 grams (Oppanol B100, BASF) Hydrogenated hydrocarbon resin 43.0 grams 5 (Escorez 5320, Exxon)
l-dodecylazacycloheptan-2-one 20.0 grams (Azone, Nelson Res., Irvine / CA) active ingredient 20.0 grams
Total 100.0 grams
Preparation: The above components are dissolved together in 150 grams of a petroleum fraction of a special boiling point 100-125, rolling on a bed of roller gears. The solution is applied to a polyester film (Hostaphan, Kalle) by means of a spreader device using a 300 micron blade, giving a coating of approximately 75 grams / square meter. After drying (15 minutes at 60 ° C), a silicone-treated polyester film (thickness of 75 microns, Laufenberg) is applied as the separation film. The finished systems are drilled in sizes and in the desired shape from 5 to 30 square centimeters, using a drilling tool. The complete systems are individually sealed in aluminized paper bags.
Example 3: Bottle containing 1.0 milligrams of dry 1-hydroxy-2- (imidazol-1-yl) -etap-1, 1-diphosphoic acid (mixed sodium salts thereof). After dilution with 1 milliliter
of water, a solution (concentration of 1 milligram / milliliter) is obtained for intravenous infusion.
Composition: Active ingredient (free diphosphonic acid) 1.0 milligrams
Mannitol 46.0 milligrams
Trisodium citrate x 2 H ^ 3 approximately 3.0 milligrams Water 1 milliliter
Water for injection 1 milliliter
In 1 milliliter of water, the active ingredient is titrated with trisodic citrate x 2 HrO until a pH of 6.0. Then mannitol is added and the solution is lyophilized, and the lyophilizate is filled in a flask.
Example 4: Ampoule containing disodium pamidronate pentahydrate dissolved in water. The solution (concentration of 3 milligrams / milliliter) is for intravenous infusion after dilution. Composition: Active ingredient 19.73 milligrams (= 15.0 milligrams of active ingredient anhydrous) Mannitol 250 milligrams Water for injection 5 milliliters
Example 5: Tablets each containing 50 milligrams of 3- [N- (2-phenylthioethyl) -N-methylamino] -l-hydroxypropane-1,1-diphosphonic acid, can be prepared as follows:
Composition (10,000 tablets) Active ingredient 500.0 grams Lactose 500.00 grams Potato starch 325.0 grams Gelatine 8.0 grams Talcum 60.0 grams Magnesium stearate 10.0 grams Silicon dioxide 20.0 grams (finely divided) Ethanol q.s.
The active ingredient is mixed with lactose and 292 grams of potato starch, and the mixture is moistened with an ethanolic solution of the gelatin, and is granulated through a sieve. After the granules have dried, the rest of the potato starch, magnesium stearate, and silicon dioxide are mixed, and the mixture is compressed to give tablets each weighing 145.0 milligrams, and containing 50.0 milligrams of active ingredient, which, if desired, can be provided with slots to break, to enable the dosage to be adjusted more finely.
Claims (18)
1. The use of a methanbisphosphonic acid derivative selected from: 3-amino-1-hydroxy-1-diphosphonic acid, 3- (N, N-dimethylamino-1-hydroxypropan-1, 1-diphosphonic acid , 4-amino-l-hydroxybutan-1, 1-diphosphonic acid, 6-amylo-l-hydroxyhexap-1, 1-diphosphonic acid, 3- (N-methyl-Nn-pentylamino) -l-hydroxypropan-10 acid , 1-diphosphonic, l-hydroxy-2- (imidazol-1-yl) ethan-1, 1-diphosphonic acid, 1-hydroxy-2- (3-pyridyl) ethan-1, 1-diphosphonic acid, and salts of N-methyl pyridinium thereof, l- (4-chlorothiophenyl) methan-l, 1-diphosphonic acid, 3- [N- (2-phenylthioethyl) -N-methylamino] -l-hydroxypropan-1, 1-diphosphonic acid l-hydroxy-3- (pyrrolidin-1-yl) propane-1,1-diphosphonic acid, 1- (N- < "• phenylaminothiocarbonyl) methan-l, 1-diphosphonic acid, tetraethylester -benzoyl-3,4-dihydro-2H-pyrazole-3,3-diphosphonic acid, 1-hydroxy-2- (imidazo [1, 2-a] pyridip-3-yl) ethan-1, 1-diphosphonic acid, and 1, 1-dichloromethane-1, acid -difosphonic, or a salt
Pharmaceutically acceptable thereof, or any hydrate thereof, for the manufacture of a pharmaceutical composition for the prevention and treatment of prosthetic loosening and migration of prostheses in mammals, including man. 2. The use according to claim 1, of a
Metanbisphosphonic acid derivative, which is selected from 3-amino-1-hydroxypropan-1, 1-diphosphonic acid, 3- (N, N-dimethylamino-1-hydroxypropan-1, 1-diphosphonic acid, 4-amino acid -1-hydroxybutan-1, 1-diphosphnalene, 6-amino-1-hydroxyhexan-1, 1-diphosphonic acid, 3- (N-methyl-Nn-pentylamino) -1-hydroxypropan-1, 1-diphosphonic acid, -hydroxy-2- (imidazol-1-yl) ethan-1, 1-diphosphonic acid, 1-hydroxy-2- (3-pyridyl) ethan-1, 1-diphosphonic acid, and N-methyl pyridinium salts thereof l- (4-chlorothiophenyl) methan-1,1-diphosphonic acid, 3- [N- (2-phenylthioethyl) -N-methylamino] -1-hydroxypropan-1, 1-diphosphonic acid, acid-hydroxy-3- ( pyrrolidin-1-yl) propan-l, 1-diphosphonic, 1- (N-phenylaminothiocarbonyl) methan-1, diphosphonic acid, 5-benzoyl-3,4-dihydro-2H-pyrazole-3-tetraethyl ester, 3-diphosphonic acid, l-hydroxy-2- (imidazo [1,2-a] pyridin-3-yl) ethan-1, 1-diphosphonic acid, a pharmaceutically acceptable salt thereof, and any hydrate of the same 3. The use according to claim 1, of a methanbisphosphonic acid derivative, which is selected from 3-amino-l-hydroxypropan-1,1-diphosphonic acid, 3- (N, N-) acid. dimethylamino-1-hydroxypropane-1, diphosphonic acid, 4-amino-1-hydroxybutan-1, 1-diphosphonic acid, 6-amino-1-hydroxyhexan-1, 1-diphosphonic acid, 3- (N-methyl-N- pentylamino) -1-hydroxypropan-1,1-diphosphonic acid, l-hydroxy-2- (imidazol-1-yl) ethan-1, 1-diphosphonic acid; l-hydroxy-2- (3-pyridyl) ethan-1, diphosphonic acid, 3- [N- (2-phenylthioethyl) -N-methylamino] -l-hydroxypropan-1,1- acid , - diphosphonic; l-hydroxy-3- (pyrrolidin-l-yl) propan-l, 1- diphosphonic acid, 1-hydroxy-2- (imidazo [1,2-a] pyridin-3-yl) ethan-1, 1- acid diphosphonic, a pharmaceutically acceptable salt thereof, and any hydrate thereof.
4. The use according to claim 1, of a methanbisphosphonic acid derivative which is selected from paronic acid, alendronic acid, 3- (N-methyl-Nn-pentylamino) -1-hydroxypropan-1, acid. diphosphonic acid, 1- hydroxy-2- (imidazol-1-yl) ethan-1, 1-diphosphonic acid, acidic acid, and tiludronic acid, a pharmaceutically acceptable salt thereof, and any hydrate thereof.
5. The use according to claim 1, of a methanbisphosphonic acid derivative, which is selected from l-hydroxy-2- (imidazol-1-yl) ethane-1,1-diphosphonic acid, and -amino-1-hydroxypropan-1, 1-diphosphonic acid, a pharmaceutically acceptable salt thereof, and any hydrate thereof
6. The use according to claim 1, of l-hydroxy-2- (imidazole) -l-yl) ethan-1, diphosphonic acid or a pharmaceutically salt thereof or any hydrate thereof
7. The use according to claim 1, of 3-amino-l-hydroxypropan-1, 1-diphosphonic acid or a pharmaceutically acceptable salt thereof or any hydrate thereof.
8. The use according to claim 1, of pamidronate disodium, or any hydrate thereof.
9. The use according to any of claims 1 to 8, wherein the prosthesis is a prosthesis of 5 hip.
10. The use according to any of claims 1 to 9, wherein the pharmaceutical composition is "- adapted for intravenous administration
11. The use according to any of claims 1 to 9, wherein the pharmaceutical composition is adapted for transdermal administration
12. The use according to any of claims 1 to 9, in wherein the pharmaceutical composition is adapted for oral administration
13. The use of a methanobisphosphonic acid derivative selected from: 3-amino-1-hydroxypropan-1, 1-diphosphonic acid, 3- (N, N-dimethylamino) -l-hydroxypropan-1, 1-diphosphonic acid, 4-amino-l-hydroxybutan-1,1-diphosphonic acid, 6-amylo-l-hydroxyhexan-1, 1-diphosphoic acid, 3- (N-methyl) acid Nn-pentylamino) -l-hydroxypropan-1,1-diphosphonic acid, l-hydroxy-2- (imidazol-1-yl) ethan-1, 1-diphosphonic acid, l-hydroxy-2- (3-? Iridyl) ethan-1, 1-diphosphonic, and N-methyl pyridinium salts thereof; l- (4-chlorothiophenyl) methan-1, 1-diphosphonic acid, 3- [N- (2-phenylthioethyl) -25 N- methylamino] -1-hydroxy propan-l, 1-diphosptopic, l-hydroxy-3- acid (pyrrole idin-1-yl) propan-1, 1-diphosphopic, 1- (N-phenylaminocarbonyl) methan-1, diphosphonic acid, 5-benzoyl-3,4-dihydro-2H-pyrazole tetraethyl ester -3,3-diphosphonic acid, l-hydroxy-2- (imidazo [1,2-a] pyridin-3-yl) ethan-1, 1-diphosphonic acid, and 1,1-dichloromethane-1,1-diphosphonic acid co; or a pharmaceutically acceptable salt thereof, or any hydrate thereof, for the prevention and treatment of prosthetic loosening and migration of prostheses in mammals, including man.
14. The use according to claim 13, of a methanbisphosphonic acid derivative, which is selected from 3-amino-l-hydroxypropan-1, 1-diphosphonic acid, 3- (N, N-dimethylamino) acid. l-hydroxypropan-1, 1-diphosphonic, 4-amino-1-hydroxybutan-1, 1-diphosphonic acid, 6-amino-1-hydroxyhexan-1, 1-diphosphonic acid, 3- (N-methyl-Nn- pentylamino) -l-hydroxypropan-1,1-diphosphonic acid, l-hydroxy-2- (imidazol-1-yl) ethan-1, diphosphonic acid, l-hydroxy-2- (3-pyridyl) ethan-l , 1-diphosphonic, and N-methyl pyridinium salts thereof; l- (4-chlorosiphenyl) methan-1, 1-diphosphonic acid, 3- [N- (2-phenylthioethyl) -N-methylamino] -1 acid -hydroxypropan-1, diphosphoic acid, l-hydroxy-3- (pyrrolidin-1-yl) propan-1,1-diphosphonic acid, 1- (N-phenylaminothiocarbonyl) methan-1, 1-diphosphonic acid, tetraethyl ester of 5-benzoyl-3,4-dihydro-2H-pyrazole-3,3-diphosphonic acid, l-hydroxy-2- (imidazo [l, 2-a] pyridin-3-yl) etap-1, 1 acid -difosphonic, a The pharmaceutically acceptable salt thereof, and any hydrate thereof.
15. A method for preventing or treating prosthetic loosening and migration of prostheses in mammals, which comprises administering to a mammal in need thereof, a therapeutically effective amount of a methanobisphosphonic acid derivative selected from: 3-amino acid -l-hydroxypropan-1, 1-diphosphonic, 3- (N, N-dimethylamino-1-hydroxypropan-1, 1-diphosphonic acid, 4-amino-1-hydroxybutan-1, 1-diphosphonic acid, 6-amino acid -l-hydroxyhexan-l, 1- diphosphonic, 3- (N-methyl-Nn-pentylamino) -l-hydroxypropan-1,1-diphosphonic acid, l-hydroxy-2- (imidazol-1-yl) ethan- l, diphosphonic acid, l-hydroxy-2- (3-pyridyl) ethan-1, 1-diphosphonic acid, and N-methyl pyridinium salts thereof; l- (4-chlorothiophenyl) methan-1 -diphosphonic acid, 3- [N- (2-phenylthioethyl) -N-methylamino] -1-hydroxypropan-1, 1-diphosphonic acid-acid-hydroxy-3- (pyrrolidin-1-yl) propan-1, 1-diphosphdane, 1- (N-phenylaminothiocarbonyl) methan-1,1-diphosphonic acid, tetraethyl ester co-acid 5-benzoyl-3,4-dihydro-2H-pyrazole-3, 3-diphosphonic acid, l-hydroxy-2- (imidazo [1,2- a] pyridin-3-yl) ethan-1, 1 -diphosphonic, and 1,1-dichloromethane-1, 1-diphosphonic acid; or a pharmaceutically acceptable salt thereof, or any hydrate thereof.
16. A method according to claim 15, wherein the methanobisphosphonic acid derivative administered is selects from 3-amino-1-hydroxypropan-1, 1-diphosphonic acid, 3- (N, N-dimethylamino-1-hydroxypropan-1, 1-diphosphonic acid, 4-amino-1-hydroxybutan-1, 1-diphosphonic, acid 6-amino-l-hydroxyhexan-l, 1-diphosphonic, 3- (N-methyl-Nn-pentylamino) -1-hydroxypropan-1, 1-diphosphonic acid, l-hydroxy-2- (imidazol-l-yl) ) ethan-1, diphosphnadic; l-hydroxy-2- (3-pyridyl) ethan-1, 1-diphosphonic acid, and N-methyl pyridinium salts thereof; l- (4-chlorothiophenyl) methan-1, 1-diphosphonic acid, 3- [N- (2-phenylthioethyl) -N-methylamino] -1-hydroxypropan-1, 1-diphosphonic acid; l-hydroxy-3- (pyrrolidin-l-yl) propan-l, l-diphosphonic acid, l- (N-phenylaminothiocarbonyl) methan-l, 1- diphosphonic acid, 5-benzoyl-3,4- tetraethyl ester dihydro-2H-pyrazole-3,3-diphosphonic acid, l-hydroxy-2- (imidazo [1,2- a] pyridin-3-yl) ethan-1, 1-diphosphonic acid, a pharmaceutically acceptable salt thereof, and any hydrate thereof.
17. A pharmaceutical composition for the prevention and loosening of prosthesis and migration of prostheses, which comprises a methanobisphosphonic acid derivative selected from: 3-amino-l-hydroxypropan-1, 1-diphosphnadic acid, 3- (N-acid , N-dimethylamino-l-hydroxypropan-1,1-diphosphonic acid, 4-amino-l-hydroxybutan-1,1-diphosphonic acid, 6-amino-l-hydroxyhexan-1, l-diphosphonic acid, 3- (N -methyl-N-pentylamino) -1-hydroxypropan-1,1-diphosphnadic acid, l-hydroxy-2- (imidazol-1-yl) ethan-1, 1-diphosphnadic acid, l-hydroxy-2- (3- pyridyl) ethan-1, diphosphonic, and N-methyl pyridinium salts thereof; l- (4-dorothiophenyl) methan-1,1-diphosphnanoic acid, 3- (N- (2-phenylthioethyl) -N-methylamino] -1-hydroxypropan-1, 1-diphosphonic acid; Acidol-hydroxy-3- (pyrrolidin-1-yl) propan-1, 1-diphosphadic acid, 1- (N-phenylaminothiocarbonyl) methan-1, 1-diphosphonic acid, 5-benzoyl-3,4-dihydro tetraethyl ester -2H-pyrazole-3, 3-diphosphonic acid, l-hydroxy-2- (imidazo [1, 2-a] pyridin-3-yl) ethan-1, 1-diphosphnadic acid, and 1,1-dichloromethane-1 acid , 1-diphosphonic; or a pharmaceutically acceptable salt thereof, or any hydrate thereof; together with a pharmaceutically acceptable vehicle.
18. A pharmaceutical composition according to claim 17, which comprises a methanobisphosphonic acid derivative selected from 3-amino-1-hydroxypropan-1,1-diphosphnanoic acid, 3- (N, N-dimethylamino-1) acid. - hydroxypropan-1,1-diphosphonic acid, 4-amino-l-hydroxybutan-1,1-diphosphonic acid, 6-amino-l-hydroxyhexan-1, 1-diphosphonic acid, acid, * "- * - (N-methyl) -N-pentylamino) -? - hydroxypropan-1,1-diphosphnadic acid, l-hydroxy-2- (imidazol-1-yl) ethan-1, 1-diphosphnadic acid 1-hydroxy-2- (3-pyridyl) ethan-1, 1-diphosphdane, and N-methyl pyridinium salts thereof; l- (4-chlorothiophenyl) methan-1, 1-diphosphonium, 3- [N- (2-phenylthioethyl) -N-methylamino] ] -1- hydroxypropan-1,1-diphosphnadic acid l-hydroxy-3- (pyrrolidin-1-yl) propan-l, 1-diphosphnadic acid, l- (N-phenylaminothiocarbonyl) methan-1, 1-diphosphnadic acid, tetraethyl ester of 5-benzoyl-3,4-dihydro-2H-pyrazol-3, 3-diphosphnadic acid, l-hydroxy-2- acid ; imidazo [1,2-a] pyridin-3-yl) ethan-1, 1-diphosphonic acid, a pharmaceutically acceptable salt thereof, and any hydrate thereof, together with a pharmaceutically acceptable carrier. SUMMARY The invention relates to the use of certain metanbisphospic acid derivatives (for the manufacture of a pharmaceutical composition), for the prevention and treatment of prosthesis loosening and migration of prostheses in mammals, including man. * * * * * Me, ANA ELENA FERRER RAMÍREZ, translator member of the Mexican Organization of Translators, A.C., with address at Av. Clavería ** > '- 224-205, Col. Clavería, México, D.F. 02080, Tels. 3962669 and 396 5201, I certify that the preceding document is, to the best of my knowledge, a faithful and accurate translation of the original document in English that I had in view. Mexico, D.F., August 14, 1996. Ana E ena Ferrer Ram rez
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9408775.6 | 1994-05-04 | ||
PCT/IB1995/000288 WO1995030421A1 (en) | 1994-05-04 | 1995-04-24 | Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration |
Publications (2)
Publication Number | Publication Date |
---|---|
MXPA96005327A true MXPA96005327A (en) | 1998-02-01 |
MX9605327A MX9605327A (en) | 1998-02-28 |
Family
ID=39165081
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX9605327A MX9605327A (en) | 1995-04-24 | 1995-04-24 | Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration. |
Country Status (1)
Country | Link |
---|---|
MX (1) | MX9605327A (en) |
-
1995
- 1995-04-24 MX MX9605327A patent/MX9605327A/en not_active IP Right Cessation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5965547A (en) | Use of certain methanebishosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration | |
AU2001274109B2 (en) | Method of administering bisphosphonates | |
RU2297229C2 (en) | Pharmaceutical biphosphonate application | |
RU2325913C2 (en) | Application of zoledrone acid, its salts, hydrates and method of antinociceptive or antiallodynic treatment of pain, method of neurotic pain treatment | |
US20070161603A1 (en) | Method of administering bisphosphonates | |
AU2001274109A1 (en) | Method of administering bisphosphonates | |
EP0600834A1 (en) | Use of methanebisphosphonic acid derivatives for the manufacture of a medicament for fracture healing | |
JP2003500352A (en) | Use of bisphosphonic acid to treat angiogenesis | |
US6255288B1 (en) | Certain methanebisphosphonic acid derivatives in fracture healing | |
RU2288722C2 (en) | Method for introducing bisphosphonates | |
MXPA96005327A (en) | Use of certain derivatives of acidometanisphisphonic to prevent the loosening of protesis and the emigration of proteins | |
CA2183764C (en) | Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration |